What changed
Medline posted Q3 FY26 Adjusted Diluted EPS of $0.44 versus the $0.35 consensus — a 27.1% beat, or $0.09 ahead. Net sales came in at $7,856M, up 10.4% YoY, with Organic Sales up 10.5%. Management raised FY2026 organic sales growth guidance to 10.0%-10.5% from 9.0%-10.0% and reaffirmed FY2026 Adjusted EBITDA of $3.3B-$3.4B. The top line was driven by existing customer growth and implementation of new customer signings from 2025, while net income of $318M slipped 1.2% on higher inventory costs tied to inflation, higher operating expenses and customer mix.
Why it matters
Medline posted Q3 FY26 Adjusted Diluted EPS of $0.44 versus the $0.35 consensus — a 27.1% beat, or $0.09 ahead. Net sales came in at $7,856M, up 10.4% YoY, with Organic Sales up 10.5%. Management rais